Treatment Patterns of Biologic Disease-Modifying Antirheumatic Drugs and Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis in Japan: A Claims-Based Cohort Study
Abstract Background Reports on treatment patterns of biologic disease-modifying antirheumatic drugs (bDMARDs)/Janus kinase inhibitors (JAKi) for rheumatoid arthritis (RA) in clinical practice are still sparse in Japan, especially in combination with conventional synthetic DMARDs (csDMARDs). Objectiv...
Saved in:
Main Authors: | Masahiko Miyashiro (Author), Teita Asano (Author), Yutaka Ishii (Author), Celine Miyazaki (Author), Hirohito Shimizu (Author), Junya Masuda (Author) |
---|---|
Format: | Book |
Published: |
Adis, Springer Healthcare,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study
by: Yun-Kyoung Song, et al.
Published: (2023) -
Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022) -
Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials
by: Tatjana Welzel, et al.
Published: (2021) -
Persistence and Safety of Golimumab in Elderly Patients with Rheumatoid Arthritis and Renal Dysfunction in a Real-World Setting
by: Seiji Yokoyama, et al.
Published: (2022) -
Correction to: Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials
by: Tatjana Welzel, et al.
Published: (2021)